Based on clinical experience in adult cancers, it has become clear that aberrant FGFR-mediated signaling is predictive of response to FGFR inhibitors in urothelial cancer (mainly driven by FGFR3 mutations) and cholangiocarcinoma (mainly driven by FGFR2 fusions). The gene discussed is FGFR3; the disease is cancer.